Short answer
Merck & Co. (MRK) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q2 2026 earnings announcement, covering Merck’s second-quarter financial results.
Merck & Co. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 earnings announcement, covering Merck’s second-quarter financial results
- Supplemental information attached as Exhibit 99.2, providing details beyond the press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 sales reached $16.6B, up 5% or 4% ex-FX, led by KEYTRUDA/QLEX at $8.4B and WINREVAIR growth of 75%
- GAAP loss per share was $0.54 versus $1.76 earnings, driven by the $2.31-per-share Terns acquisition charge
- Terns acquisition adds MK-4208, an investigational BCR::ABL1 inhibitor with FDA Breakthrough Therapy designation
- 2026 sales outlook raised to $66.3B-$67.3B from $65.8B-$67.0B, signaling stronger operating momentum
- Non-GAAP EPS outlook cut to $2.66-$2.76 from $5.04-$5.16, reflecting Terns and Cidara acquisition charges totaling $5.93 per share
Item EX-99.2 · Exhibit EX-99.2
- Q2 sales $16,607M, up 5%; pharmaceutical sales rose 5% and Animal Health advanced 8%
- GAAP net loss attributable to Merck $1,335M, or $(0.54) diluted EPS, versus $4,427M income in Q2 2025
- R&D expense surged to $9,741M from $4,048M, driving the quarterly loss and signaling heavy investment or acquisition-related costs
- Keytruda sales fell 1% to $7,904M, while Winrevair rose 75% to $588M and Welireg increased 67% to $271M
- June YTD interest expense rose to $1,004M from $618M, adding pressure alongside elevated costs and restructuring charges
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Merck & Co. 8-K filings
Get the next MRK 8-K as it lands
Follow MRK for push alerts, or ask the research agent what this filing means.